GSEA further corroborated that RTN4 is involved in LGG progression via tumour‐related signalling pathways and inflammatory responses, indicating that targeted modulation of RTN4 could serve as a potential therapeutic strategy for LGG treatment. Here, RTN4 is linked to neoplasm.